SCHEMBL7010992

SCHEMBL7010992

NCCCCCCNS(=O)(=O)c1ccc(F)cc1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.53
KMT2A Q03164 5/20 0.53
ALDH1A1 P00352 5/20 0.53
PKM P14618 1/20 0.53
CYP3A4 P08684 7/20 0.52
CYP1A2 P05177 6/20 0.52
CYP2C9 P11712 6/20 0.52
CYP2C19 P33261 6/20 0.52
SCN1A P35498 3/20 0.52
SCN2A Q99250 3/20 0.52
SCN3A Q9NY46 3/20 0.52
KDM4E B2RXH2 1/20 0.52
HSD17B10 Q99714 1/20 0.52
TP53 P04637 5/20 0.50
CYP2D6 P10635 5/20 0.50
MAPK1 P28482 3/20 0.50
TSHR P16473 2/20 0.50
THPO P40225 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7005708 1.00 MEN1 (0.53) MEN1KMT2AALDH1A1PKMCYP3A4
SCHEMBL4141122 0.85 CYP3A4 (0.56) MEN1KMT2AALDH1A1PKMCYP3A4
SCHEMBL14360846 0.81 CCR1 (0.52) MEN1KMT2AALDH1A1PKMCYP3A4
SCHEMBL1775171 0.80 LMNA (0.51) KMT2AALDH1A1PKMCYP2C19LMNA
SCHEMBL5441643 0.78 CNR2 (0.48) MEN1KMT2AALDH1A1PKMCYP3A4
SCHEMBL2941883 0.76 LMNA (0.52) KMT2AALDH1A1LMNAFABP4CXCR4
SCHEMBL2566906 0.76 CCR2 (0.49) KMT2AALDH1A1MAPTLMNAPOLB
SCHEMBL30902183 0.73 POLB (0.50) ALDH1A1LMNAPOLBCXCR4KCNH2
SCHEMBL4128136 0.73 CYP3A4 (0.58) MEN1KMT2AALDH1A1CYP3A4CYP1A2
SCHEMBL15145890 0.72 ALDH1A1 (0.77) MEN1KMT2AALDH1A1PKMCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225007-A1 Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases APOTEX INC. 2003-12-04 US disclosed
EP-1348710-A1 Sulfonamide derivatives of 3-substituted imidazo[1,2-D]-1,2,4-thiadiazoles and 3-substituted-[1,2,4]thiadiazolo[4,5-A]benzimidazole as inhibitors of fibrin cross-linking and transglutaminases Apotex Inc. (CA) 2003-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225007-A1 Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases PIGS, FGB, SERPINE1 MEN1 3661/4885KMT2A 1952/4885ALDH1A1 689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.